Skip to main content
Top
Gepubliceerd in: Tijdschrift voor Urologie 8/2011

01-12-2011 | Bevacizumab met interferon-alfa voor gemetastaseerd niercelcarcinoom

Bevacizumab in combinatie met interferon-alfa voor gemetastaseerd niercelcarcinoom: veiligheid en toepasbaarheid in de praktijk

Auteurs: Dr. P. M. M. B. Soetekouw, Drs. A. Beeker, Dr. A. Bex, Dr. C. J. van Groeningen, Prof. Dr. P. F. A. Mulders

Gepubliceerd in: Tijdschrift voor Urologie | Uitgave 8/2011

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

samenvatting

De angiogeneseremmer bevacizumab is, in combinatie met interferon- alfa-2a (IFNα), geregistreerd als eerstelijnsbehandeling van gevorderd en gemetastaseerd niercelcarcinoom. In dit artikel gaan we in op de toepassing van deze behandeloptie in de context van verdraagbaarheid en veiligheid, in het bijzonder van de interferoncomponent.
Klinisch onderzoek heeft aangetoond dat dosisreductie van IFNα een effectieve strategie is voor het optimaliseren van de verdraagbaarheid van bevacizumab in combinatie met IFNα.
Literatuur
2.
go back to reference Amato R. Modest effect of interferon alfa on metastatic renal-cell carcinoma. Lancet. 1999 Jan 2;353:6–7. Amato R. Modest effect of interferon alfa on metastatic renal-cell carcinoma. Lancet. 1999 Jan 2;353:6–7.
4.
go back to reference Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.PubMedCrossRef Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.PubMedCrossRef
10.
go back to reference Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8)2530–40.PubMed Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8)2530–40.PubMed
11.
go back to reference Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–12.PubMedCrossRef Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008;26(32):5204–12.PubMedCrossRef
12.
go back to reference Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.PubMedCrossRef Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8.PubMedCrossRef
13.
go back to reference Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58(3):398–406.PubMedCrossRef Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58(3):398–406.PubMedCrossRef
16.
go back to reference Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III studie. Lancet 2007;370:2103–11.PubMedCrossRef Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III studie. Lancet 2007;370:2103–11.PubMedCrossRef
17.
go back to reference Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overal survival. J Clin Oncol. 2010;28(13):2144–50.PubMedCrossRef Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overal survival. J Clin Oncol. 2010;28(13):2144–50.PubMedCrossRef
18.
go back to reference Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422–8.PubMedCrossRef Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26(33):5422–8.PubMedCrossRef
19.
go back to reference Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al. Phase III studie of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28:2137–43.PubMedCrossRef Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al. Phase III studie of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28:2137–43.PubMedCrossRef
20.
go back to reference Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet. 2010;375(9715):641–8.PubMedCrossRef Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet. 2010;375(9715):641–8.PubMedCrossRef
21.
go back to reference Federico M, Frassoldati A, Lamparelli T, Foà R, Brugiatelli M, Annino L, et al. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooparative Group for HCL. Ann Oncol. 1994;5:725–31.PubMed Federico M, Frassoldati A, Lamparelli T, Foà R, Brugiatelli M, Annino L, et al. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooparative Group for HCL. Ann Oncol. 1994;5:725–31.PubMed
22.
go back to reference Castaigne S, Sigaux F, Cantell K, Falcoff E, Boiron M, Flandrin G, et al. Interferon Alpha in the treatment of hairy cell leukemia. Cancer. 1986;56:1681–4.CrossRef Castaigne S, Sigaux F, Cantell K, Falcoff E, Boiron M, Flandrin G, et al. Interferon Alpha in the treatment of hairy cell leukemia. Cancer. 1986;56:1681–4.CrossRef
23.
go back to reference Quesada JR, Gutterman JU, Hersh EM.Treatment of hairy cell leukemia with alpha interferons. Cancer. 1986;57:1678–80.PubMedCrossRef Quesada JR, Gutterman JU, Hersh EM.Treatment of hairy cell leukemia with alpha interferons. Cancer. 1986;57:1678–80.PubMedCrossRef
24.
go back to reference Berman E, Heller G, Kempin S, Gee T, Tran LL, Clarkson B. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood. 1990;75(4):839–45.PubMed Berman E, Heller G, Kempin S, Gee T, Tran LL, Clarkson B. Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood. 1990;75(4):839–45.PubMed
25.
go back to reference Saven A, Piro LD. Treatment of Hairy Cell Leukemia. Blood. 1992;79(5):1111–20.PubMed Saven A, Piro LD. Treatment of Hairy Cell Leukemia. Blood. 1992;79(5):1111–20.PubMed
26.
go back to reference Melichar B, Koralewski P, Ravaud A, Pluzanska A, Bracarda S, Szczylik C, et al. First-line bevacizumab combined with reduced dose interferon α 2a is active in patients with metastatic renal cell carcinoma. Ann Oncol. 2008;19(8):1470–6.PubMedCrossRef Melichar B, Koralewski P, Ravaud A, Pluzanska A, Bracarda S, Szczylik C, et al. First-line bevacizumab combined with reduced dose interferon α 2a is active in patients with metastatic renal cell carcinoma. Ann Oncol. 2008;19(8):1470–6.PubMedCrossRef
27.
go back to reference Melichar B, Bracarda S, Matveev V, Rusakov I, Kaprin A, Zyryanov A, et al. BEVLIN: Prospective study of the safety and efficacy of first-line bevacizumab + low-dose interferon a2A in patients with metastatic renal cell carcinoma. J Clin Oncol. 2011;29(Suppl; abstr 4546). Melichar B, Bracarda S, Matveev V, Rusakov I, Kaprin A, Zyryanov A, et al. BEVLIN: Prospective study of the safety and efficacy of first-line bevacizumab + low-dose interferon a2A in patients with metastatic renal cell carcinoma. J Clin Oncol. 2011;29(Suppl; abstr 4546).
28.
go back to reference Gabrilovich D, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996 Oct;2(10):1096–103. Gabrilovich D, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996 Oct;2(10):1096–103.
29.
go back to reference Gabrilovich D, Chen HL, Girgis KR, Cunningham HT, Meny GM. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92(11):4150–66.PubMed Gabrilovich D, Chen HL, Girgis KR, Cunningham HT, Meny GM. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92(11):4150–66.PubMed
30.
go back to reference Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5(10):2963–70.PubMed Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5(10):2963–70.PubMed
31.
go back to reference Von Marschall Z, Scholz A, Cramer T, Schäfer G, Schirner M, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003;95:437–48.CrossRef Von Marschall Z, Scholz A, Cramer T, Schäfer G, Schirner M, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003;95:437–48.CrossRef
32.
go back to reference Persano L, Moserle L, Esposito G, Bronte V, Barbieri V, Iafrate M, et al. Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. Carcinogenesis. 2009;30(5):851–60.PubMedCrossRef Persano L, Moserle L, Esposito G, Bronte V, Barbieri V, Iafrate M, et al. Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. Carcinogenesis. 2009;30(5):851–60.PubMedCrossRef
33.
go back to reference Indraccolo S. Interferon-alpha as angiogenesis inhibitor: learning from tumor models. Autoimmunity. 2010;43(3):244–7.PubMedCrossRef Indraccolo S. Interferon-alpha as angiogenesis inhibitor: learning from tumor models. Autoimmunity. 2010;43(3):244–7.PubMedCrossRef
34.
go back to reference Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A. Targeted delivery of IFN-gamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res. 2005;65:2906–13.CrossRef Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A. Targeted delivery of IFN-gamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res. 2005;65:2906–13.CrossRef
35.
go back to reference Tedjarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ, et al. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clin Cancer Res. 2002;8:2413–22.PubMed Tedjarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ, et al. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel. Clin Cancer Res. 2002;8:2413–22.PubMed
36.
go back to reference Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferonalpha- mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999;5(10):2726–34.PubMed Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ. Interferonalpha- mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res. 1999;5(10):2726–34.PubMed
Metagegevens
Titel
Bevacizumab in combinatie met interferon-alfa voor gemetastaseerd niercelcarcinoom: veiligheid en toepasbaarheid in de praktijk
Auteurs
Dr. P. M. M. B. Soetekouw
Drs. A. Beeker
Dr. A. Bex
Dr. C. J. van Groeningen
Prof. Dr. P. F. A. Mulders
Publicatiedatum
01-12-2011
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Tijdschrift voor Urologie / Uitgave 8/2011
Print ISSN: 2211-3037
Elektronisch ISSN: 2211-4718
DOI
https://doi.org/10.1007/s13629-011-0096-4

Andere artikelen Uitgave 8/2011

Tijdschrift voor Urologie 8/2011 Naar de uitgave

Een 59-jarige vrouw met een 5 cm grote urethrasteen

Een 59-jarige vrouw met een 5 cm grote urethrasteen

Een knoop in de urinekatheter van een 3 jaar oud meisje

Een knoop in de urinekatheter van een 3-jarig meisje

EditorialNotes

Editorial